Skip to Content
Merck
  • An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer.

An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer.

Cell reports. Medicine (2024-02-08)
Veronica Ruta, Chiara Naro, Marco Pieraccioli, Adriana Leccese, Livia Archibugi, Eleonora Cesari, Valentina Panzeri, Chantal Allgöwer, Paolo Giorgio Arcidiacono, Massimo Falconi, Carmine Carbone, Giampaolo Tortora, Federica Borrelli, Fabia Attili, Cristiano Spada, Giuseppe Quero, Sergio Alfieri, Claudio Doglioni, Alexander Kleger, Gabriele Capurso, Claudio Sette
ABSTRACT

Pancreatic ductal adenocarcinoma (PDAC) is characterized by extremely poor prognosis. PDAC presents with molecularly distinct subtypes, with the basal-like one being associated with enhanced chemoresistance. Splicing dysregulation contributes to PDAC; however, its involvement in subtype specification remains elusive. Herein, we uncover a subtype-specific splicing signature associated with prognosis in PDAC and the splicing factor Quaking (QKI) as a determinant of the basal-like signature. Single-cell sequencing analyses highlight QKI as a marker of the basal-like phenotype. QKI represses splicing events associated with the classical subtype while promoting basal-like events associated with shorter survival. QKI favors a plastic, quasi-mesenchymal phenotype that supports migration and chemoresistance in PDAC organoids and cell lines, and its expression is elevated in high-grade primary tumors and metastatic lesions. These studies identify a splicing signature that defines PDAC subtypes and indicate that QKI promotes an undifferentiated, plastic phenotype, which renders PDAC cells chemoresistant and adaptable to environmental changes.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-KRT18 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
5-Fluorouracil, ≥99% (HPLC), powder
Sigma-Aldrich
Protease Inhibitor Cocktail, for use with mammalian cell and tissue extracts, DMSO solution
Sigma-Aldrich
Anti-RBM47 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-QKI antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
N-Acetyl-L-cysteine, BioReagent, suitable for cell culture